AKRX - Akorn, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
19.02
-0.13 (-0.68%)
As of 10:49AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close19.15
Open19.04
Bid18.99 x 1000
Ask19.00 x 800
Day's Range18.89 - 19.29
52 Week Range10.76 - 33.63
Volume221,411
Avg. Volume2,255,742
Market Cap2.386B
Beta1.71
PE Ratio (TTM)N/A
EPS (TTM)-1.48
Earnings DateMay 18, 2017 - May 19, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1991-05-24
1y Target Est27.25
Trade prices are not sourced from all markets
  • RBC Is Bullish on Generic Pharma: Upgrades MYL, AMRX, ENDO, AKRX
    Market Realist4 days ago

    RBC Is Bullish on Generic Pharma: Upgrades MYL, AMRX, ENDO, AKRX

    RBC Is Bullish on Generic Pharma: Upgrades MYL, AMRX, ENDO, AKRXRBC updates its view on the generic pharma industry

  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markit8 days ago

    See what the IHS Markit Score report has to say about Akorn Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • GlobeNewswire16 days ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Five Prime Therapeutics, Akorn, The Blackstone Group, Avaya, Tractor Supply, and CymaBay Therapeutics — New Research Emphasizes Economic Growth

    NEW YORK, Aug. 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Five ...

  • ACCESSWIRE17 days ago

    Complimentary Technical Snapshots on Akorn and Three More Generic Drugs Stocks

    WallStEquities.com revisits the Generic Drugs market, which can be segmented into biosimilars, simple generic, and super generic. Based on its therapeutics applications, the generic drugs market can be classified into cardiovascular products, anti-infective drugs, anti-arthritis drugs, central nervous system drugs, anti-cancer drugs, respiratory products, and others. Under assessment this morning are these four stocks: Agile Therapeutics Inc. (NASDAQ: AGRX), Akorn Inc. (NASDAQ: AKRX), Collegium Pharmaceutical Inc. (NASDAQ: COLL), and Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX).

  • ACCESSWIRE18 days ago

    Today's Research Reports on Trending Tickers: Aurora Cannabis and Akorn

    NEW YORK, NY / ACCESSWIRE / July 30, 2018 / U.S. markets plunged on Friday, after Twitter reported disappointing second quarter earnings and gross domestic product reflected fairly strong economic growth, ...

  • ACCESSWIRE24 days ago

    Oversold Biotechnology Companies

    Microcapspeculators.com is an informational website that is highly interested in exploring development stage companies, enroute to finding companies with the best potential HENDERSON, NV / ACCESSWIRE / ...

  • Akorn Fell 6.8% on July 13, Fresenius-Akorn Merger Woes Continue
    Market Realistlast month

    Akorn Fell 6.8% on July 13, Fresenius-Akorn Merger Woes Continue

    On July 13, Akorn (AKRX) shares fell ~6.8% and closed at $17.91. Currently, Akorn stock is trading higher than its 50-day moving average of $15.83, while the stock is trading lower than its 200-day moving average of $21.04. According to Mats Henriksson, chief executive of a Fresenius unit, Fresenius spent two years addressing the problems with one of its plants in India.

  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Akorn Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding AKRX totaled $640 million.

  • Akorn (AKRX) Looks Good: Stock Adds 7.8% in Session
    Zackslast month

    Akorn (AKRX) Looks Good: Stock Adds 7.8% in Session

    Akorn (AKRX) was a big mover last session, as the company saw its shares rise more than 7% on the day, amid huge volumes.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Akorn and Momenta Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / July 13, 2018 / U.S. markets made it in the green on Thursday, pushed higher by rally in information technology and telecom stocks, covering continued uncertainty over trade ...

  • Fresenius Had Testing Woes Similar to Akorn, Unit Head Says
    Bloomberglast month

    Fresenius Had Testing Woes Similar to Akorn, Unit Head Says

    A Fresenius SE executive acknowledged his company has grappled with testing problems similar to those the German health-care company cited as a basis for pulling out of a $4.3 billion deal to buy U.S. generic drugmaker Akorn Inc. Mats Henriksson, chief executive of a Fresenius unit, testified Thursday that U.S. Food and Drug Administration inspectors in 2013 questioned drug-injection testing and test-result storage at one of the firm’s plants in India. It took the company two years to address those problems, Henriksson told Delaware Chancery Judge Travis Laster.

  • Execution blocked after company objects to use of its drug
    Associated Presslast month

    Execution blocked after company objects to use of its drug

    A twice-convicted killer who wants to die rather than spend his life in prison was about an hour from eating his final meal Wednesday when he found out a Nevada judge had indefinitely delayed his execution after a pharmaceutical company objected to the use of one of its drugs to put someone to death. Instead of carrying out what would have been the first execution in Nevada since 2006 and the first in the U.S. using an untried combination of three drugs, state officials must now reassess their options. Scott Raymond Dozier, 47, was put on suicide watch as a precaution while officials planned a psychological evaluation at the state prison in the remote northeastern city of Ely before he returns to death row.

  • Akorn CEO Says Fresenius Is Using Smear Campaign to Cancel Deal
    Bloomberglast month

    Akorn CEO Says Fresenius Is Using Smear Campaign to Cancel Deal

    Akorn Inc.’s top executive complained Fresenius SE officials are unfairly smearing his firm’s reputation as the German company tries to pull out of $4.3 billion deal to to buy the generic drugmaker. Raj Rai, Akorn’s chief executive officer since 2010, told a judge Tuesday Fresenius’s claims that flaws in the company’s computer system led to fraudulent test results aren’t true. Akorn says that Fresenius is using minor mistakes to create a pretext for backing out of the the $34-per-share buyout.

  • Lax Drugmaker Computer Security Linked to Deal Cancellation
    Bloomberglast month

    Lax Drugmaker Computer Security Linked to Deal Cancellation

    John Avellanet, a consultant Akorn hired in 2016 after regulators questioned its operational procedures, discovered executives had little security control over the pharma company’s computer system and that raised doubts about the integrity of its record-keeping, said Lewis Clayton, a lawyer representing Fresenius SE in a trial over the failed merger. Akorn shares fell as much as 4.6 percent, the most intraday since May 3. Fresenius officials say Akorn’s testing miscues, along with a history of operational problems that drew warnings from the U.S. Food and Drug Administration, justified canceling the $34-per-share deal.

  • Akorn Was Warned About Problems Before Merger, Executive Says
    Bloomberglast month

    Akorn Was Warned About Problems Before Merger, Executive Says

    A consultant warned Akorn Inc. before its merger with Fresenius SE about production-line problems that raised questions about the integrity of data it provided to drug regulators, an Akorn executive testified as a trial over the failed $4.3 billion deal began. The consultant, hired to review procedures and operations at Akorn’s Decatur, Illinois, facility in 2016, found cameras recording drug vials coming down a line didn’t properly store pictures used to check cleanliness and safety, Kim Wasserkrug, an Akorn vice president, told Delaware Chancery Court Judge Travis Laster. Fresenius officials contend manufacturing problems at the Decatur plant and others, along with Akorn’s submission of allegedly phony data to federal regulators, are justifications for nixing the $34-per-share deal.

  • TEVA or AKRX: Which Is the Better Value Stock Right Now?
    Zackslast month

    TEVA or AKRX: Which Is the Better Value Stock Right Now?

    TEVA vs. AKRX: Which Stock Is the Better Value Option?

  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Akorn Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • ACCESSWIRE2 months ago

    Free Technical Research on Akorn and Three More Generic Drugs Equities

    WallStEquities.com has selected the following Generic Drugs stocks for review today: Adamas Pharmaceuticals Inc. (NASDAQ: ADMS), Agile Therapeutics Inc. (NASDAQ: AGRX), Akorn Inc. (NASDAQ: AKRX), and Allergan PLC (NYSE: AGN). Companies in the generic pharmaceuticals sector make drugs that are offered cheaper than name-brand pharmaceuticals once patents for the more expensive drugs lapse.

  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Akorn Inc.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 2. Index (PMI) data, output in the Healthcare sector is rising.

  • GlobeNewswire2 months ago

    Lawsuit for Investors in shares of Akorn, Inc. (NASDAQ: AKRX) announced by Shareholders Foundation

    SAN DIEGO, June 04, 2018-- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Akorn, Inc. shares. Investors who purchased shares of Akorn, Inc. in March 2017 ...

  • Options Traders Expect Huge Moves in Akorn (AKRX) Stock
    Zacks3 months ago

    Options Traders Expect Huge Moves in Akorn (AKRX) Stock

    Investors in Akorn (AKRX) need to pay close attention to the stock based on moves in the options market lately.

  • Moore Kuehn, PLLC Announces an Investigation Involving Possible Breaches of Fiduciary Duties by Officers and Directors of Akorn, Inc.
    PR Newswire3 months ago

    Moore Kuehn, PLLC Announces an Investigation Involving Possible Breaches of Fiduciary Duties by Officers and Directors of Akorn, Inc.

    NEW YORK , May 29, 2018 /PRNewswire/ -- Moore Kuehn, PLLC is investigating potential claims for breach of fiduciary duty involving the directors and officers of Akorn, Inc. (NASDAQ: AKRX ).  On February ...

  • Reuters3 months ago

    Fresenius CEO defends cancelled Akorn deal

    FRANKFURT/BERLIN, May 18 (Reuters) - Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn, saying it was the only option after uncovering data integrity breaches at the U.S drugmaker. "It was certainly not an easy decision, but ultimately there was only one correct course," CEO Stephan Sturm, a former investment banker and experienced dealmaker, said at Fresenius' annual shareholder meeting in Frankfurt on Friday. Sturm served as chief financial officer before taking over as CEO in 2016 and has helped build the German company into a globally diversified healthcare group through a series of multi-billion dollar deals.